Vaishali Pharma Ltd (NSE: VAISHALI) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹102 Cr, it ranks #3,255 by market cap among the 6,137 Indian listed companies on FinBizNet, and #70 of 86 in Medicinal Chemicals and Botanical Products. At ₹6.87 (as of 25 Oct 2026), the share price is 38.4% below its 52-week high of ₹11.15 and 44.6% above its 52-week low of ₹4.75. The share price is down 33.9% over one year and down 11.5% over three months.
| Current Price | ₹6.87 |
|---|---|
| Market Cap | ₹102 Cr |
| NSE Symbol | VAISHALI |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 23.7 |
| Return on Equity | 1.52% |
| Return on Assets | 1.88% |
| 52-Week Range | ₹4.75 – ₹11.15 |
| 1-Year Price Change | -33.9% |
| 3-Month Price Change | -11.5% |
| Beta (1Y) | 0.3 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.vaishalipharma.com |
| Revenue | ₹23 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 6.5% |
| EPS (Basic) | ₹0.12 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutica
1. Sale of Pharmaceutical Products-This segment offers pharmaceutical formulations, active pharmaceutical ingredients, surgical products, veterinary supplements, and herbal and nutraceutical products.
1. Sale of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Vaishali Pharma Ltd | ₹102 Cr | 23.7 | 1.52% | ₹23 Cr | -33.9% |
Listed by market capitalisation. Ratios are shown for context only.
Vaishali Pharma Ltd is trading at ₹6.87, with a market capitalisation of ₹102 Cr.
Vaishali Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Vaishali Pharma Ltd has a P/E of 23.7 and a return on equity of 1.52%.
Vaishali Pharma Ltd is listed on the NSE under the symbol VAISHALI.
Vaishali Pharma Ltd's share price is down 33.9% over one year and down 11.5% over three months. Its 52-week range is ₹4.75 to ₹11.15.
In Q1 FY27, Vaishali Pharma Ltd reported revenue of ₹23 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.12 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.